Should You Buy Dynavax Stock in 2025? Complete AE Guide

What is Dynavax?

How much is Dynavax stock?

The price of Dynavax stock is rising this week. As of now, the stock trades at $9.76, reflecting a 2.74% gain over the past 24 hours, but a 0.41% decrease for the week. Dynavax’s market capitalization stands at $1.17 billion, with an average three-month trading volume of 2.64 million shares.

Since the company is not currently profitable, there is no P/E ratio available, and no dividend yield is offered. The stock carries a beta of 1.26, pointing to volatility higher than the overall market—a factor investors in the UAE should consider when evaluating its growth potential.

Our full analysis of the Dynavax stock

After reviewing Dynavax Technologies Corporation’s latest financials and benchmarking it against its last three years of performance, we combined proprietary quantitative and technical analyses with sector and peer comparison to present a comprehensive outlook. This methodology incorporates analyst consensus, fundamental data, and market sentiment for a nuanced perspective. Why could Dynavax reemerge as a strategic entry into the high-growth biotech sector in 2025?

Recent Performance and Market Context

Dynavax (NASDAQ: DVAX) has displayed notable resilience within a challenging biotech market in 2024–2025. On May 30, 2025, the stock traded at $9.76 (+2.74% intraday), despite some short-term volatility: -0.41% over the past week, -24.1% in six months, and -15.4% year-over-year. While these movements signal a corrective phase, they also suggest the stock is consolidating near long-term support.

The Q1 2025 earnings release showed a record $65 million in net HEPLISAV-B revenues, up 36% year-over-year and beating forecasts. This demonstrates Dynavax’s execution strength and its growing market share. The broader US and global healthcare landscape also remains robust—government initiatives and rising adult immunization demand reinforce sector momentum.

• Record quarterly revenues driven by HEPLISAV-B expansion.
• A “Moderate Buy” analyst consensus, with a compelling average price target of $24.53—implying approximately 151% upside from current levels.
• A strong US biotech and vaccine market backdrop, supported by regulatory tailwinds and public health policy.

Collectively, these trends indicate Dynavax is at an inflection point—transitioning from a defensive correction to potential renewed outperformance.

Technical Analysis

Technical indicators put Dynavax at a pivotal technical juncture. The stock is trading tightly between $9.50 and $9.85, just above its key 52-week low support at $9.22. This strong support, repeatedly tested yet holding, signals the potential for a bottoming process—often a precursor to bullish reversals in biotech stocks.

• Momentum Indicators:
• The RSI is rebounding from oversold levels, indicating reduced selling and growing buyer interest.
• The MACD, though recently negative, is flattening. A cross above the signal line could confirm a momentum shift.
• Moving Averages:
• Share price remains below both its 50- and 200-day moving averages, but these are within striking distance. A close above $10.00 would be a positive technical signal.
• Support and Resistance:
• Major support: $9.22 (52-week low).
• Key resistance: $14.63 (recent annual high), serving as a medium-term price target.

In summary, Dynavax is shaping up a technical base, with potential for upside as momentum indicators turn positive and as it approaches key resistance levels.

Fundamental Analysis

• Revenue Growth: Quarterly revenue rose to $68.2 million, up 34% year-over-year; HEPLISAV-B generated $65 million (+36% y/y), consolidating its leading market position.
• Profitability Trajectory: The loss per share of -$0.50 was mainly driven by R&D investments and pipeline development. Management reaffirmed 2025 HEPLISAV-B revenue guidance of $305–325 million, signaling confidence in continued growth.
• Attractive Valuation: Dynavax’s $1.17 billion market cap and $24.53 average analyst target signal compelling forward value, especially considering sector multiples. Although the stock remains loss-making (no P/E), rapid revenue growth could soon improve profitability.
• Structural Strengths & Innovation:
• Leadership in vaccine adjuvant technologies (CpG 1018), pivotal for next-generation vaccines.
• Dominant 43% market share in the US adult hepatitis B vaccine segment (Q1 2025)—a high-growth niche.
• Active R&D pipeline—investments in new vaccines and adjuvants support powerful long-term growth.

Versus peers in biotechnology and specialty vaccines, Dynavax combines commercialized product revenues and late-stage pipeline innovation, giving it a unique position.

Volume and Liquidity

Dynavax’s average daily trading volume of 2.64 million shares indicates strong market interest and liquidity—a key consideration for both institutional and retail investors. With a public float of 114.5 million shares from 120.08 million outstanding, the stock offers price efficiency and a lower risk of high volatility during major trades.

High liquidity and float support institutional confidence and make Dynavax highly suitable for a range of investment strategies.

Catalysts and Positive Outlook

• Expansion of HEPLISAV-B: 43% US market share for adult hepatitis B vaccines in Q1 2025—with management targeting further growth in untapped segments.
• R&D Pipeline: New vaccine and adjuvant program announcements provide avenues for future revenue.
• Corporate Governance and Management: A recently appointed chief accounting officer brings expertise and process improvement.
• Shareholder Activism: While Deep Track Capital's engagement adds operational scrutiny, it may also drive reforms and higher accountability.
• Sector Support: Regulatory and policy environment in the US favors vaccine innovation, while global health trends will continue to drive demand.

Alongside a strong analyst buy rating (average target $24.53), these catalysts reinforce the potential for renewed upside.

Investment Strategies

For investors considering Dynavax, present conditions appear well aligned for new positions. Arguments by time horizon include:

• Short-term (Swing):
• Trading close to technical low (support at $9.22) with oversold signals and rising positive news flow—for potential near-term rebounds.
• Suitable for tactical traders seeking a swift move on possible news catalysts (product updates, analyst upgrades).
• Medium-term (6–12 months):
• Record growth figures and sector leadership position Dynavax as a 'growth at a reasonable price' opportunity.
• Expansion and pipeline milestones present clear, date-driven upside events.
• Long-term:
• Sustained market leadership in hepatitis B vaccines, adjuvant innovation, and an expanding R&D pipeline imply long-term compounding potential.
• Attractive valuation offers favorable risk-reward for biotech-focused portfolios.

Disciplined position sizing and close monitoring of news, earnings, and R&D updates can help optimize risk-adjusted returns across all horizons.

Is It the Right Time to Buy Dynavax?

Dynavax currently stands as a compelling opportunity for investors aiming for biotechnology sector exposure at an attractive valuation. The combination of robust, growing revenues, dominant market share in critical vaccine categories, and a dynamic innovation pipeline builds a strong investment case. Technically, the stock is consolidating at long-term support, with a sizable gap to analyst consensus price targets.

Amid supportive sector trends, improving fundamentals, and numerous tangible catalysts, Dynavax could be crossing into a new bullish phase—warranting serious consideration for inclusion in both growth and innovation-focused portfolios. For investors tracking a merger of technical bottoming, fundamental strength, and news-driven momentum, Dynavax represents an excellent prospect within the biotech landscape in 2025.

With a sharp focus on innovation and robust growth, Dynavax could define the future of vaccine technology—delivering investors both conviction and the potential for significant returns.

How to buy Dynavax stock in the AE?

Buying Dynavax stock online is both simple and secure when you use a regulated broker licensed in your region. Investors in the UAE can choose between two main methods: purchasing the shares outright (spot/cash buying), or trading Dynavax via CFDs (Contracts for Difference) for access to leverage. Each method offers its own benefits and considerations, making it important to select the approach that best suits your goals and risk appetite. If you’re ready to compare regulated brokers and their fees for Dynavax, you’ll find a comprehensive broker comparison further down this page.

Cash Buying

A cash purchase of Dynavax means you directly buy and own real Dynavax shares, which are held securely in your brokerage account. When buying in cash, typical fees with UAE-friendly brokers are usually a fixed commission per order—often around $3–$10 (or equivalent in AED, approx. AED 11–37).

Example

If the Dynavax share price is $9.76 and you invest $1,000, including a brokerage fee of $5, you can buy approximately 101 shares ($1,000 – $5 = $995 → $995 ÷ $9.76 ≈ 101 shares).
✔️ Gain scenario:
If the share price rises by 10%, your holding becomes worth $1,100.
Result: That’s a gross gain of +$100, delivering a +10% return on your investment (before any taxes or additional fees).

Trading via CFD

CFD trading lets you speculate on the price movement of Dynavax shares without owning the underlying asset. When trading Dynavax CFDs, you typically pay a spread (the difference between buy and sell price), and an overnight financing charge if you hold the position for more than a day. CFDs are popular for their easy access to leverage, but it’s important to be mindful of increased risks.

Example

With a $1,000 margin and 5x leverage, you gain exposure to $5,000 worth of Dynavax stock as a CFD.
✔️ Gain scenario:
If the stock rises by 8%, your total position increases by 8% × 5 = 40%.
Result: That’s a $400 gain on your initial $1,000 deposit (excluding spread and overnight financing fees).

Final Advice

Before you start investing, it’s crucial to compare each broker’s fees, account types, and trading conditions—costs can vary significantly between platforms, and this impacts your overall return. Choosing between cash buying and CFD trading should reflect your personal objectives, risk profile, and investment strategy. If you’d like to review the leading UAE and international brokers for Dynavax, our detailed comparison awaits you further down the page.

Our 7 tips for buying Dynavax stock

The latest news about Dynavax

Dynavax has reported record Q1 2025 revenues, driven by HEPLISAV-B vaccine growth. For the first quarter of 2025, Dynavax achieved $68.2 million in total revenue, marking a 34% year-over-year increase. The vast majority of this growth is attributed to the commercial success of HEPLISAV-B, its hepatitis B vaccine, which alone generated $65 million, up 36% from the prior year. This momentum is directly relevant for analysts in AE given the strong regional focus on infectious disease prevention and the increasing adoption of advanced immunization solutions within the Gulf’s public health agendas. The positive revenue trend provides further evidence of Dynavax’s market leadership in the hepatitis B prevention space, which is notable for both healthcare providers and pharmaceutical distributors in the region.

The company has issued bullish guidance for full-year 2025, anticipating continued sales expansion for HEPLISAV-B. Dynavax projects HEPLISAV-B revenues between $305 million and $325 million for 2025, building on its 43% market share in the United States by Q1. This robust outlook reinforces the company’s commitment to increasing global vaccine access—an initiative closely aligned with the priorities of AE’s national health strategy, which supports enhanced immunization programs and is open to collaboration with innovative suppliers. Such growth prospects may attract attention from local institutional investors as well as healthcare procurement authorities seeking proven, scalable vaccine supply partners.

Consensus among analysts remains positive, with a moderate buy rating and substantial upside reflected in price targets. Market sentiment has stabilized around a “Moderate Buy” to “Buy” consensus, with at least five to nine covering analysts and a mean price target of $24.53—over 150% above current trading levels. While the share price is presently $9.76, short-term performance has been steady and recent trading reflects confidence in management’s strategic plan. This sentiment may encourage AE-based investors to monitor DVAX as a candidate for both mid-term growth and strategic portfolio diversification, especially given the region’s increasing interest in healthcare innovation and bioscience equities.

Dynavax continues to innovate, expanding its vaccine pipeline and strengthening its leadership in adjuvant technology. In the past week, the company highlighted its ongoing development of new vaccine candidates and reaffirmed its position as a leader in vaccine adjuvant technology with its proprietary CpG 1018 platform. This emphasis on R&D is particularly relevant as AE’s biopharmaceutical sector invests heavily in transformative healthcare technologies and seeks partnership opportunities with cutting-edge vaccine developers. Dynavax’s expanding pipeline and proven adjuvant expertise position it as a credible collaborator for potential joint ventures or strategic alliances within the UAE and broader Gulf region.

No material negative events or regulatory setbacks impacting AE or Middle Eastern interests have been reported in the last seven days. The past week has seen no adverse developments regarding product distribution, regulatory status, or strategic initiatives specific to the UAE or Gulf markets. With global market access intact and a strong operational performance, Dynavax remains well-positioned to benefit from further regional engagement, including prospective entry into the AE biotech ecosystem should local demand for hepatitis B vaccination continue to rise in line with public health initiatives.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.